We are really excited to announce two amazing new hires at Dash Bio: Sejuti Sengupta and Dmitri Konorev, PhD! Sejuti was most recently at Arbor where she lead the development of cell based potency assays for multiple CRISPR-based programs and delivery modalities, such as LNP, AAV, mRNA/gRNA electroporation. She has a deep background in pharmacology and immunology which will be invaluable as we build our bioanalysis platform. Dmitri is a Mass Spectrometry expert with a diverse background both in small molecule bioanalysis and proteomics. He was most recently at IDEXX, leading comprehensive LC/MS proteomic analyses as well as developing and optimizing LC/MS methods for biomarker discovery. Sejuti and Dmitri will be working closely with Ely Porter, Olga Seltser and the rest of the team as we build out our next-gen tech-based bioanalysis platform.
About us
At Dash Bio, we're revolutionizing clinical bioanalysis to expedite drug development. By leveraging AI and robotics, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average for clinical trials and GLP studies. While AI startups have transformed drug discovery, the development phase remains bogged down by manual, labor-intensive processes. We're changing that narrative. Our tech-first products automate critical steps, reducing costs and time to market without compromising on quality. Our initial product line focuses on clinical bioanalysis—the testing of samples from clinical trial subjects. With a fresh perspective, we've built a modern platform where quality, automation, and regulation work seamlessly together. Why settle for traditional methods when you can invest in results? We're obsessed with enhancing customer experience and outcomes, constantly pushing boundaries to make processes better and faster. Meet Our Leadership Team: Dave Johnson, CEO: Former Chief Data and AI Officer at Moderna. Ander Tallett, COO: Led Enterprise Systems at Moderna and Resilience. Ely Porter, CSO: Co-founder and CTO of Rootpath. Together, we're crafting a future where bioanalysis is intuitive, data flows effortlessly, and drugs reach the market faster than ever before. Join us on this journey. Learn more at dash.bio
- Website
-
https://dash.bio
External link for Dash Bio
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2024
Locations
-
Primary
Get directions
56 Broad St
Boston, Massachusetts 02109, US
Employees at Dash Bio
-
Matt Whitfield
Head of Software Engineering at Dash Bio
-
Sejuti Sengupta
Bioanalysis | Translational research | Cell and gene therapy |
-
Jennifer Pond MS MBA
Biotechnology leader with 21 years of experience in quality, manufacturing, supporting innovative drug discovery and development. Proven track record…
-
Dave Johnson
Co-founder & CEO at Dash Bio
Updates
-
Really excited to have Ben on the team! We are growing quickly as we work to bring our innovative bioanalysis solutions to market, and great to have Ben join to help us expand our flexible automation platform!
I’m happy to share that I’m starting a new position as Principal Automation Engineer at Dash Bio!
This content isn’t available here
Access this content and more in the LinkedIn app
-
Last week, our founders, Dave Johnson and Ander Tallett were thrilled to show our lab to our investors Maria (Brewer) Palma, Brett Wilson, and Amol Sarva. They were able to experience first hand the legacy, manual approach to running ELISAs with our CSO Ely Porter. Then our Head of Automation Olga Seltser, and our Head of Software Engineering Matt Whitfield showed them the future with our fully-automated and integrated bioanalysis platform. With our tech-first approach, we'll be able to deliver clinical bioanalysis results with unparalleled quality and unprecedented speed. More to come. We move fast 🚀 #Dash #bioanalysis #clinical
-
-
An interview with our co-founder Ander Tallett: "In many ways, we’re living through a golden age of biotech and AI-powered drug discovery. But all of the AI models in research won’t matter if we can’t fix development." "Disruption in Clinical Development is needed, overdue, and hugely impactful to patients. AWS unlocked the software industry, we will unlock biotech."
-
Great to have you on the team Matt Whitfield!
After a couple of refreshing months honing my skills as an interior designer, chef, small engine and appliance repairman, gardener, landscaper, cyclist, ant farmer, Tolkien historian, and soccer chauffeur, I am pumped to join Dash Bio to lead software engineering! What started as a pet peeve in college and pet-project as a grad student/post-doc has become the driving force behind my career: reducing repetitive, manual lab processes and experiment analysis through targeted/intelligent use of software solutions. At Dash, we’re building a next-gen, highly-automated lab leveraging AI and robotics. First up, transforming clinical bioanalysis by improving speed and quality of results.
This content isn’t available here
Access this content and more in the LinkedIn app
-
Our CEO Dave Johnson goes through his Moderna experiences, challenges with drug development, and what Dash Bio will change.
We've got a very exciting episode of Data in Biotech to share. Ross Katz sat down with Dave Johnson - former Chief Data and Artificial Intelligence Officer at Moderna and now CEO and Co-founder of Dash Bio - to talk about how his new venture is set to revolutionize clinical bioanalysis and streamline drug development. Dave takes us back to the early research days in Moderna, where he helped lay the groundwork for mRNA technology, which later enabled the development of a vaccine for COVID-19 at unprecedented speed. He also highlights what he sees as the most impactful insufficiencies in drug development—particularly the lack of industrialization and standardization— and how Dash Bio aims to address these issues. The goal— he tells us—is ultimately to develop a more efficient, high-quality end-to-end system and improve the overall efficacy of the drug development process. Ross and Dave also touch upon Dave’s vision for the future of Dash Bio, plus his advice for aspiring biotech data leaders eager to contribute to industry transformation. Listen wherever you get your podcasts. Apple: https://lnkd.in/d8BDwZ9Q Spotify: https://lnkd.in/dtG7GRRK #DataInBiotech #BiotechInnovation #DrugDevelopment #podcast
-
-
Dash Bio reposted this
Excited to work with Dave Johnson, Ely Porter, and Ander Tallett, a purpose-driven team helping to bring drugs to market faster and cheaper. Dash Bio
Today, I’m thrilled to announce the public launch of my new startup, Dash Bio. I’ve spent my career leveraging technology and AI to transform biotech R&D. After almost a decade at Moderna, I left a year ago to found Dash with the mission to transform drug development industry-wide. Despite all of the innovation and countless AI startups in drug discovery, there has been little innovation in drug development, where the majority of time and cost is spent to bring a drug to market. Until now. At Dash, we believe that the way to unlock the biotech industry is by reinventing drug development, starting with a next-gen, highly-automated clinical bioanalysis lab. On this journey, I’m thrilled to be partnering with my co-founder, Ander Tallett, our founding CSO, Ely Porter, and an incredibly talented team. Read more about how we’re transforming drug development in The Wall Street Journal and on our website dash.bio. And if you are a development-stage biotech looking for a radically different experience with a clinical bioanalysis vendor, we’d love to hear from you! https://lnkd.in/eK46Rifr
-
Dash Bio reposted this
Founder and investor, LifeX Ventures, Aikito, Knotel, Peek, Virgin Mobile, McKinsey, Stanford and Columbia
Proud for LifeX Ventures to be a little part of this amazing story with Dave and Ander Tallett !
Today, I’m thrilled to announce the public launch of my new startup, Dash Bio. I’ve spent my career leveraging technology and AI to transform biotech R&D. After almost a decade at Moderna, I left a year ago to found Dash with the mission to transform drug development industry-wide. Despite all of the innovation and countless AI startups in drug discovery, there has been little innovation in drug development, where the majority of time and cost is spent to bring a drug to market. Until now. At Dash, we believe that the way to unlock the biotech industry is by reinventing drug development, starting with a next-gen, highly-automated clinical bioanalysis lab. On this journey, I’m thrilled to be partnering with my co-founder, Ander Tallett, our founding CSO, Ely Porter, and an incredibly talented team. Read more about how we’re transforming drug development in The Wall Street Journal and on our website dash.bio. And if you are a development-stage biotech looking for a radically different experience with a clinical bioanalysis vendor, we’d love to hear from you! https://lnkd.in/eK46Rifr
-
Dash Bio reposted this
Excited to share Freestyle Capital is leading the $6.5M seed round for Dash Bio, an innovator in tech-enabled services for drug development. Congrats to Ander Tallett & Dave Johnson, we're thrilled to be on the journey with you 👏
Today, I’m thrilled to announce the public launch of my new startup, Dash Bio. I’ve spent my career leveraging technology and AI to transform biotech R&D. After almost a decade at Moderna, I left a year ago to found Dash with the mission to transform drug development industry-wide. Despite all of the innovation and countless AI startups in drug discovery, there has been little innovation in drug development, where the majority of time and cost is spent to bring a drug to market. Until now. At Dash, we believe that the way to unlock the biotech industry is by reinventing drug development, starting with a next-gen, highly-automated clinical bioanalysis lab. On this journey, I’m thrilled to be partnering with my co-founder, Ander Tallett, our founding CSO, Ely Porter, and an incredibly talented team. Read more about how we’re transforming drug development in The Wall Street Journal and on our website dash.bio. And if you are a development-stage biotech looking for a radically different experience with a clinical bioanalysis vendor, we’d love to hear from you! https://lnkd.in/eK46Rifr